The latest developments in oral insulin: scientific advances and clinical progress
Journal of Pharmacy and Pharmacology · 03.07.2026 · 78 (7)
DOI: 10.1093/jpp/rgag078 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Pharmacy and Pharmacology, online erschienen am 22.07.2026. Verfasst von Hui-Fang Chang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Department of Internal Medicine, Hsinchu Mackay Memorial Hospital, Hsinchu 300, Taiwan. Hauptthemen laut MEDLINE: Insulin, Hypoglycemic Agents, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 106 Literaturangaben. Gefördert von: Center for Intelligent Drug Systems and Smart Bio-devices (IDS2B), Ministry of Education.
Abstract (Originalsprache)
Objectives Diabetes mellitus remains a global health challenge, with insulin therapy essential for type 1 diabetes and many advanced type 2 cases. However, reliance on subcutaneous injections limits adherence and quality of life. This review synthesizes recent advances in oral insulin research, encompassing scientific rationale, delivery technologies, clinical progress, regulatory perspectives, and commercial outlook. Key findings Peer-reviewed studies, clinical trial data and industry reports were analyzed to assess the efficacy, safety, and translational potential of oral insulin formulations. Oral insulin offers physiological advantages by mimicking endogenous portal vein delivery, potentially reducing peripheral hyperinsulinemia and hypoglycemia risk. Advances in nanotechnology, permeation enhancers, and enteric coatings have improved bioavailability, though variability persists. Late-stage candidates such as Oramed’s ORMD-0801 and Diabetology’s Capsulin demonstrated feasibility but yielded mixed Phase 3 outcomes, underscoring translational gaps. Regulators emphasize rigorous pharmacokinetic characterization and long-term safety, while commercial viability depends on scalability, affordability, and patient-centered benefits. Summary Oral insulin represents a transformative innovation in diabetes care, with potential to improve adherence, quality of life, and hepatic glucose regulation. Despite setbacks in pivotal trials, ongoing technological refinement, strategic partnerships, and integration with personalized medicine and digital health tools continue to advance its path toward clinical adoption.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology, Department of Internal Medicine, Hsinchu Mackay Memorial Hospital, Hsinchu 300, Taiwan.
- Department of Biological Science and Technology, National Yang Ming Chiao Tung University, Hsinchu 300, Taiwan.
- Animal and Plant Health and Production Research Center, Agricultural Technology Research Institute, Hsinchu 300, Taiwan.
- Division of Pharmacy, Koo Foundation Sun Yat-Sen Cancer Center, Taipei 100, Taiwan.
- Center for Intelligent Drug Systems and Smart Bio-devices (IDS2B), National Yang Ming Chiao Tung University, Hsinchu 300, Taiwan.
ORCID-Profile: Chih-Sheng Lin
Förderung
- Center for Intelligent Drug Systems and Smart Bio-devices (IDS2B)
- Ministry of Education
Zitieren
APA
Chang, H. F., Lin, T. M., Sun, Y. L., Lin, T. C., & Lin, C. S. (2026). The latest developments in oral insulin: scientific advances and clinical progress. Journal of Pharmacy and Pharmacology, 78(7). https://doi.org/10.1093/jpp/rgag078
Vancouver
Chang HF, Lin TM, Sun YL, Lin TC, Lin CS. The latest developments in oral insulin: scientific advances and clinical progress. Journal of Pharmacy and Pharmacology. 2026;78(7). doi:10.1093/jpp/rgag078
BibTeX
@article{Chang2026,
author = {Chang, Hui-Fang and Lin, Tzu-Min and Sun, Yu-Ling and Lin, Tzu-Ching and Lin, Chih-Sheng},
title = {The latest developments in oral insulin: scientific advances and clinical progress},
journal = {Journal of Pharmacy and Pharmacology},
year = {2026},
volume = {78},
number = {7},
doi = {10.1093/jpp/rgag078}
}
EUVIMED